Vij, R., & Raab, M. (2020). First-in-human phase I study of ABBV-838, an antibody-drug conjugate targeting SLAMF7/CS1 in patients with relapsed and refractory multiple myeloma. Clinical cancer research, 26(10), . https://doi.org/10.1158/1078-0432.CCR-19-1431
Chicago-Zitierstil (17. Ausg.)Vij, Ravi, und Marc-Steffen Raab. "First-in-human Phase I Study of ABBV-838, an Antibody-drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma." Clinical Cancer Research 26, no. 10 (2020). https://doi.org/10.1158/1078-0432.CCR-19-1431.
MLA-Zitierstil (9. Ausg.)Vij, Ravi, und Marc-Steffen Raab. "First-in-human Phase I Study of ABBV-838, an Antibody-drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma." Clinical Cancer Research, vol. 26, no. 10, 2020, https://doi.org/10.1158/1078-0432.CCR-19-1431.